We are live on
!
Find out more
RhumbLine Advisers Portfolio holdings
AUM
$117B
1-Year Est. Return
29.66%
This Fund
S&P 500
This Quarter
Est. Return
+9.63%
1 Year Est. Return
+29.66%
3 Year Est. Return
+101.47%
5 Year Est. Return
+137.35%
10 Year Est. Return
+530.92%
AUM
$59.8B
AUM Growth
+$5.07B
(+9.3%)
Cap. Flow
+$518M
Cap. Flow
% of AUM
0.87%
Top 10 Holdings %
Top 10 Hldgs %
18.08%
Holding
2,992
New
38
Increased
2,357
Reduced
537
Closed
43
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$68M |
| 2 |
Truist Financial
TFC
|
+$55.9M |
| 3 |
ServiceNow
NOW
|
+$33.3M |
| 4 |
Uber
UBER
|
+$21.4M |
| 5 |
Las Vegas Sands
LVS
|
+$15.7M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
CELG
Celgene Corp
CELG
|
+$119M |
| 2 |
STI
SunTrust Banks, Inc.
STI
|
+$55.9M |
| 3 |
Apple
AAPL
|
+$48.3M |
| 4 |
iShares TIPS Bond ETF
TIP
|
+$22M |
| 5 |
VIAB
Viacom Inc. Class B
VIAB
|
+$16.4M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 19.57% |
| 2 | Financials | 15.53% |
| 3 | Healthcare | 13.38% |
| 4 | Consumer Discretionary | 10.07% |
| 5 | Industrials | 9.99% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
KRA
1626
DELISTED
Kraton Corporation
KRA
| $2.72M | ﹤0.01% |
107,515
+5,457
| +5% | +$132K |
|
1627
Axcelis
ACLS
$4.2B
| $2.71M | ﹤0.01% |
112,526
+5,435
| +5% | +$114K |
|
1628
Newmark Group
NMRK
$2.77B
| $2.71M | ﹤0.01% |
201,424
+2,823
| +1% | +$32.9K |
|
1629
Houlihan Lokey
HLI
$8.96B
| $2.71M | ﹤0.01% |
55,437
+4,528
| +9% | +$214K |
|
1630
CorVel
CRVL
$3.19B
| $2.69M | ﹤0.01% |
92,301
+3,747
| +4% | +$99.7K |
|
1631
DigitalBridge
DBRG
$2.94B
| $2.69M | ﹤0.01% |
141,459
+7,555
| +6% | +$156K |
|
1632
SiriusPoint
SPNT
$2.74B
| $2.68M | ﹤0.01% |
254,900
+11,911
| +5% | +$116K |
|
|
UBA
1633
DELISTED
Urstadt Biddle Properties Inc. Class A
UBA
| $2.68M | ﹤0.01% |
107,930
+6,629
| +7% | +$159K |
|
1634
Core Laboratories
CLB
$502M
| $2.68M | ﹤0.01% |
71,139
-2,725
| -4% | -$122K |
|
1635
Banc of California
BANC
$3.07B
| $2.67M | ﹤0.01% |
155,602
+12,148
| +8% | +$184K |
|
|
HTZ
1636
DELISTED
Hertz Global Holdings, Inc.
HTZ
| $2.67M | ﹤0.01% |
169,718
+7,364
| +5% | +$110K |
|
1637
Freshpet
FRPT
$3.51B
| $2.67M | ﹤0.01% |
45,195
+2,316
| +5% | +$123K |
|
1638
Koppers
KOP
$981M
| $2.67M | ﹤0.01% |
69,868
+2,828
| +4% | +$99.3K |
|
|
PGRE
1639
DELISTED
Paramount Group
PGRE
| $2.67M | ﹤0.01% |
191,712
+8,386
| +5% | +$113K |
|
1640
Vicor
VICR
$10.1B
| $2.67M | ﹤0.01% |
57,042
+3,190
| +6% | +$121K |
|
1641
Heron Therapeutics
HRTX
$95.5M
| $2.66M | ﹤0.01% |
113,227
+12,425
| +12% | +$275K |
|
1642
Hecla Mining
HL
$11.1B
| $2.66M | ﹤0.01% |
784,128
+12,486
| +2% | +$30.6K |
|
|
BDN
1643
Brandywine Realty Trust
BDN
$551M
| $2.65M | ﹤0.01% |
168,552
+10,218
| +6% | +$154K |
|
1644
Beyond Meat
BYND
$314M
| $2.65M | ﹤0.01% |
35,123
+23,613
| +205% | +$2.19M |
|
1645
Cohen & Steers
CNS
$4.33B
| $2.65M | ﹤0.01% |
42,242
-189
| -0.4% | -$12K |
|
1646
STAAR Surgical
STAA
$1.14B
| $2.65M | ﹤0.01% |
75,326
+2,077
| +3% | +$68.5K |
|
|
RDFN
1647
DELISTED
Redfin
RDFN
| $2.65M | ﹤0.01% |
125,244
+6,692
| +6% | +$128K |
|
1648
NETGEAR
NTGR
$659M
| $2.64M | ﹤0.01% |
107,581
+4,452
| +4% | +$122K |
|
1649
Invesco S&P 500 Equal Weight ETF
RSP
$99.3B
| $2.64M | ﹤0.01% |
22,789
+90
| +0.4% | +$10K |
|
|
TDAY
1650
USA Today Co
TDAY
$1.27B
| $2.63M | ﹤0.01% |
412,960
+218,527
| +112% | +$1.6M |
|
Similar funds
VAM
RhumbLine Advisers's Q4 2019 Portfolio in Review
As of Q4 2019, RhumbLine Advisers held 2,992 positions worth $59.8B, up 9.3% from $54.7B the previous quarter. Its ten largest holdings account for 18% of the portfolio.
Trading was light in Q4 2019: portfolio turnover was 2.7%. RhumbLine Advisers opened 38 new positions and exited 43, leaving the 2,992-position portfolio largely intact.
By sector, the portfolio is most concentrated in Technology at 20% of assets, up from 19% a quarter earlier, followed by Financials and Healthcare.
- RhumbLine Advisers's largest Q4 2019 buy was Envista: 126,664 shares worth $3.75M.
- RhumbLine Advisers added most to Bristol-Myers Squibb in Q4 2019, an estimated $68M increase.
- RhumbLine Advisers's biggest Q4 2019 reduction was Apple, cutting an estimated $48.3M.
- RhumbLine Advisers fully exited Celgene Corp in Q4 2019, selling an estimated $119M.
- RhumbLine Advisers's ten largest holdings make up 18% of its $59.8B portfolio in Q4 2019.
- RhumbLine Advisers opened 38 new positions and closed 43 in Q4 2019.
- RhumbLine Advisers's portfolio value rose 9.3% quarter-over-quarter to $59.8B.
Based on RhumbLine Advisers's 13F filing for Q4 2019, filed 5 Feb 2020.